These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 23228017

  • 1. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.
    Chen ZY, Shi M, Peng LX, Wei W, Li XJ, Guo ZX, Li SH, Zhong C, Qian CN, Guo RP.
    J Transl Med; 2012 Dec 10; 10():245. PubMed ID: 23228017
    [Abstract] [Full Text] [Related]

  • 2. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.
    Huynh H, Chow PK, Tai WM, Choo SP, Chung AY, Ong HS, Soo KC, Ong R, Linnartz R, Shi MM.
    J Hepatol; 2012 Mar 10; 56(3):595-601. PubMed ID: 22027573
    [Abstract] [Full Text] [Related]

  • 3. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
    Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH, Lin MW, Chen PJ, Chen KF.
    Mol Cancer Ther; 2012 Feb 10; 11(2):452-63. PubMed ID: 22180308
    [Abstract] [Full Text] [Related]

  • 4. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.
    Cheng AL, Thongprasert S, Lim HY, Sukeepaisarnjaroen W, Yang TS, Wu CC, Chao Y, Chan SL, Kudo M, Ikeda M, Kang YK, Pan H, Numata K, Han G, Balsara B, Zhang Y, Rodriguez AM, Zhang Y, Wang Y, Poon RT.
    Hepatology; 2016 Sep 10; 64(3):774-84. PubMed ID: 27082062
    [Abstract] [Full Text] [Related]

  • 5. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF, Chen HL, Liu CY, Tai WT, Ichikawa K, Chen PJ, Cheng AL.
    Biochem Pharmacol; 2012 Mar 15; 83(6):769-77. PubMed ID: 22230479
    [Abstract] [Full Text] [Related]

  • 6. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
    Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, Geissler EK, Stoeltzing O, Lang SA.
    Mol Cancer Ther; 2011 Nov 15; 10(11):2157-67. PubMed ID: 21885862
    [Abstract] [Full Text] [Related]

  • 7. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
    Huynh H, Ong R, Soo KC.
    Angiogenesis; 2012 Mar 15; 15(1):59-70. PubMed ID: 22187171
    [Abstract] [Full Text] [Related]

  • 8. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
    Chan SL, Wong CH, Lau CP, Zhou Q, Hui CW, Lui VW, Ma BB, Chan AT, Yeo W.
    Cancer Chemother Pharmacol; 2013 Jun 15; 71(6):1417-25. PubMed ID: 23546591
    [Abstract] [Full Text] [Related]

  • 9. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma.
    Yang C, Qin S.
    Cancer Med; 2018 Sep 15; 7(9):4570-4583. PubMed ID: 30109780
    [Abstract] [Full Text] [Related]

  • 10. Plumbagin restrains hepatocellular carcinoma angiogenesis by suppressing the migration and invasion of tumor-derived vascular endothelial cells.
    Wei Y, Yang Q, Zhang Y, Zhao T, Liu X, Zhong J, Ma J, Chen Y, Zhao C, Li J.
    Oncotarget; 2017 Feb 28; 8(9):15230-15241. PubMed ID: 28122355
    [Abstract] [Full Text] [Related]

  • 11. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM, Gebhard DF, Andresen CJ.
    Eur J Gastroenterol Hepatol; 2012 May 28; 24(5):563-74. PubMed ID: 22314934
    [Abstract] [Full Text] [Related]

  • 12. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
    Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y, Matsui J.
    Cancer Med; 2018 Jun 28; 7(6):2641-2653. PubMed ID: 29733511
    [Abstract] [Full Text] [Related]

  • 13. Targeting multiple tyrosine kinase receptors with Dovitinib blocks invasion and the interaction between tumor cells and cancer-associated fibroblasts in breast cancer.
    Zang C, Eucker J, Habbel P, Neumann C, Schulz CO, Bangemann N, Kissner L, Riess H, Liu H.
    Cell Cycle; 2015 Jun 28; 14(8):1291-9. PubMed ID: 25714853
    [Abstract] [Full Text] [Related]

  • 14. Dovitinib Acts As a Novel Radiosensitizer in Hepatocellular Carcinoma by Targeting SHP-1/STAT3 Signaling.
    Huang CY, Tai WT, Wu SY, Shih CT, Chen MH, Tsai MH, Kuo CW, Shiau CW, Hung MH, Chen KF.
    Int J Radiat Oncol Biol Phys; 2016 Jun 01; 95(2):761-71. PubMed ID: 26960749
    [Abstract] [Full Text] [Related]

  • 15. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
    Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD, Soo KC.
    J Hepatol; 2010 Jan 01; 52(1):79-87. PubMed ID: 19910069
    [Abstract] [Full Text] [Related]

  • 16. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J.
    Clin Cancer Res; 2013 Jul 01; 19(13):3693-702. PubMed ID: 23658459
    [Abstract] [Full Text] [Related]

  • 17. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.
    Hong SW, Jung KH, Lee HS, Choi MJ, Son MK, Zheng HM, Hong SS.
    Cancer Sci; 2012 Nov 01; 103(11):1929-37. PubMed ID: 22909393
    [Abstract] [Full Text] [Related]

  • 18. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST.
    Cancer Res; 2005 May 01; 65(9):3691-9. PubMed ID: 15867364
    [Abstract] [Full Text] [Related]

  • 19. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
    Konecny GE, Kolarova T, O'Brien NA, Winterhoff B, Yang G, Qi J, Qi Z, Venkatesan N, Ayala R, Luo T, Finn RS, Kristof J, Galderisi C, Porta DG, Anderson L, Shi MM, Yovine A, Slamon DJ.
    Mol Cancer Ther; 2013 May 01; 12(5):632-42. PubMed ID: 23443805
    [Abstract] [Full Text] [Related]

  • 20. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
    Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, Pollock P, Byron S, Tran E.
    Clin Cancer Res; 2008 Oct 01; 14(19):6146-53. PubMed ID: 18829493
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.